AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00224770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MIS+Cathflo Activase (drug)
Description: MIS+Cathflo Activase (drug): The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3 or 1.0mg of rt-PA, CathFlo® through the catheter once every eight hours for up to 72 hours, in addition to best medical care.
Study NCT00224770 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative stereotactic CT-Guided Endoscopic Surgery
Description: Mechanical intracerebral hemorrhage removal via an endoscope utilizing the same operative targeting arm as MISTIE arm. No rt-PA administered, and in addition to best medical care.
Study NCT02366897 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Manus Sensor Pen
Description: Manus Sensor Pen as made by Manus Neurodynamica Ltd
Study NCT03808610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03808610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT03808610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO
Study NCT03808610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT03808610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine
Description: Given IV
Study NCT03808610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV
Study NCT03808610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT03808610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT03808610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT03808610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT03729102 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood drawn after rabies vaccine booster vaccination
Description: All participants would be given one dose of rabies vaccine and monitor the immunological cells i.e., regulatory T cell, regulatory B cell, T follicular helper cells, cytokines i.e., IL-10, TGF-Beta, and Rabies neutralizing antibody titers, before and after the booster injection
Study NCT03729102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood drawn after rabies vaccine booster vaccination
Description: All participants would be given one dose of rabies vaccine and monitor the immunological cells i.e., regulatory T cell, regulatory B cell, T follicular helper cells, cytokines i.e., IL-10, TGF-Beta, and Rabies neutralizing antibody titers, before and after the booster injection
Study NCT02950857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPEG
Description: (Pegylated erythropoeitin)
Study NCT01862952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: starting of anti-epileptic drug treatment
Study NCT01038401 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: A sample of venous blood will also be collected
Description: These samples of blood will be use to characterize the residual viral populations on effective HAART in three compartments, plasma, monocytes, and GALT
Study NCT03644901 — intervention group
Intervention type: PROCEDURE
Intervention: nonsurgical periodontal treatment
Description: patients will undergo nonsurgical periodontal treatment to reduce the relative attachment level and improve the probing depth. An initial session will be conducted to remove supra gingival plaque and calculus. another appointment is set to perform full moth scalling and root planing.
Study NCT03736343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: Participants will complete two drinking sessions.
Study NCT00004935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin™ (Her)
Description: Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy
Study NCT00004935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin™ (Her) + chemo
Description: Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy
Study NCT04344041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol 200,000 IU
Description: Patients receive a vitamin D supplementation of 400,000 IU in a single oral dose.
Study NCT04344041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol 50,000 IU
Description: Patients receive a vitamin D supplementation of 50,000 IU in a single oral dose
Study NCT03276637 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Whole exome sequencing
Description: Whole exome sequencing at 125x coverage (i.e., at least 125 sequencing reads covering each position within the exome region of interest) performed at the Laboratory of Molecular Medicine's Clinical Laboratory Improvement Amendments (CLIA) certified laboratory on 75 enrolled individuals
Study NCT04425343 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: 16s RNA Metagenomics sequencing
Description: The subgingival plaque was collected using a sterile curette from the buccal aspect of maxillary molars and lingual aspect of mandibular incisors, in a vial containing 200µl of Buffer CL.
Study NCT02450721 — intervention group
Intervention type: OTHER
Intervention: Biomarkers serum level measurement
Description: Biomarker serum level measurement was performed with ELISA using following kits: Lp-PL-A2 ELISA- Cloud-CloneCorp. (USA); PAPP-A ELISA- IBL (Germany); Lp (a) ELISA Kit-AssayPro (USA ), ADMA ELISA Kit- ImmunDiagnostik ( Germany); hsCRP ELISA- Biomerica (Germany); according to the manufacturer's instructions . Absorbance of standards and samples was measured with a microplate reader Bio-Tek (USA) at a wavelength specified by the kit manufacturer . The calculation of the determined biomarkers concentration was performed using the software SOFTmaxPRO.
Study NCT02088203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 1
Description: Russian Tarragon Nutrasorb 0.3 g
Study NCT02272842 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin B12
Description: Vitamin B12 in a multivitamin paste.
Study NCT02088203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 2
Description: Russian Tarragon Nutrasorb 1 g
Study NCT02272842 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Vitamin B12 in a multivitamin paste.
Study NCT02088203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 0
Description: Placebo
Study NCT02088203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 3
Description: Russian Tarragon Nutrasorb 3 g
Study NCT02088203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 4
Description: Russian Tarragon Nutrasorb 10 g
Study NCT02088203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 5
Description: Russian Tarragon Nutrasorb 20 g
Study NCT02088203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 6
Description: Russian Tarragon Nutrasorb 30 g
Study NCT00798343 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Seasonal vaccine
Description: Non-adjuvanted seasonal influenza vaccine (total dose 45ug)
Study NCT00798343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5 vaccine
Description: MF59-adjuvanted A/Vietnam/1194 H5N1 vaccine 7.5ug dose
Study NCT02602132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clamping
Description: To clamp before the removal of short-term indwelling urethral catheters
Study NCT03551717 — intervention group
Intervention type: OTHER
Intervention: Optical Coherence Tomography angiography
Description: At the inclusion visit for all patients and at M3 only for 50 patients.
Study NCT02722343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir intravaginal ring
Description: The participant will wear the intravaginal ring consecutively for 14 days and nights. Following study product use and at study visit 4, blood and genital tract samples will be taken (to include cervico-vaginal fluid and tissue)
Study NCT02722343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Description: The participant will take the tablet for 14 days. taking one tablet each morning. Following study product use and at study visit 4, blood and genital tract samples will be taken (to include cervico-vaginal fluid and tissue)
Study NCT02183935 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duodena-jejunal liner
Study NCT03933384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir alafenamide
Description: Tenofovir alafenamide 25mg/tab once daily
Study NCT03933384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Entecavir 0.5mg/tab once daily
Study NCT02710305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral hyoscine butyl bromide tablets plus lidocaine cream
Description: patients will take oral hyoscine butyl bromide 30 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before the procedure
Study NCT03551717 — intervention group
Intervention type: OTHER
Intervention: Fundus
Description: At the inclusion visit for all patients and at M3 only for 50 patients.
Study NCT02710305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo tablets plus placebo cream
Description: patients will take oral placebo 30 minutes before the procedure plus placebo cream placed into their cervix immediately before the procedure
Study NCT00327184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b- and meningococcal serogroup C (vaccine)
Description: Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.
Study NCT03551717 — intervention group
Intervention type: OTHER
Intervention: cardiac ultrasound scan
Description: Only for 50 patients, 3 months after the initial cardiovascular event
Study NCT04119076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classroom-based physical activity
Study NCT04119076 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Study NCT00327184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix Penta
Description: Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.
Study NCT00327184 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa
Description: Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age
Study NCT03514485 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yes We Can Children's Asthma Program
Description: The Yes We Can Children's Asthma Program intervention is a medical-social model based on a chronic care approach, including risk stratification, clinical care management, social care coordination by a community health worker, and primary care physician asthma champions. This intervention includes asthma education, trigger reduction visits and care coordination. There will be five clinic visits and four home visits over 12 months implemented by the primary care CHW who is integrated into the primary care practice.
Study NCT00327184 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Neis-Vac-C
Description: Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age
Study NCT03514485 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: School-Based Asthma Therapy
Description: School-Based Asthma Therapy includes enhanced care coordination for prescribed daily controller medication. The school nurse will coordinate with teachers and the school CHW to schedule daily controller asthma medication administration. The school CHW will assist in obtaining a current asthma care plan and medication administration form from the primary care provider.
Study NCT03514485 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Open Airways for School Plus
Description: Open Airways for Schools Plus was designed to improve the asthma self-management skills in children and enhance control of asthma in the school. The school intervention includes:~1. Open Airways for Schools curriculum for all students with asthma. Classes will be conducted by the school CHW once each semester.~2. Environmental classroom assessments conducted by school CHWs for students enrolled in the study. These teachers will receive classroom supplies to create a more asthma-friendly classroom environment.~3. Asthma education for school staff/personnel at the start of each school year.~4. School facility walk-through assessments to detect potential environmental asthma triggers will be conducted by the School District of Philadelphia.
Study NCT04637581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wraparound
Description: Wraparound is a 12-month family-driven intensive care coordination model.
Study NCT02480374 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMNN-001
Study NCT02655016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered.
Study NCT02655016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study NCT04459715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xevinapant (Debio 1143)
Description: Xevinapant (Debio 1143) administrated as oral solution from Day 1 to 14, every 21-day cycle.
Study NCT04459715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin administered as an IV infusion every 3 weeks (Q3W).
Study NCT04459715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin administered as an IV infusion every 3 weeks (Q3W).
Study NCT04459715 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulation Radiation Therapy (IMRT)
Description: 70 Gy given in 35 fractions over 7 weeks.
Study NCT04459715 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulation Radiation Therapy (IMRT)
Description: 70 Gy given in 35 fractions over 7 weeks.
Study NCT04459715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matched placebo administrated as oral solution from Day 1 to 14, every 21-day cycle.
Study NCT04310397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO
Study NCT04310397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Given IV
Study NCT04310397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT04310397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT02779764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: Oral
Study NCT03644485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus immediate-release formulation
Description: oral
Study NCT03644485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus prolonged-release formulation
Description: oral
Study NCT03644485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction therapy
Description: All participants will receive induction therapy. The dosage and administration of induction immunotherapy will be a single kind of drug determined by the investigator.
Study NCT03644485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid drugs
Description: All participants will receive mycophenolic acid drugs in combination with corticosteroids. The dosage and administration of mycophenolic acid will be determined by the investigator.
Study NCT03644485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: All participants will receive corticosteroids in combination with mycophenolic acid drugs. The dosage and administration of corticosteroids will be determined by the investigator.
Study NCT03626363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management
Description: An eight week stress reduction course.
Study NCT03626363 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management
Description: An eight week stress reduction course.
Study NCT01290978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep
Description: The application sites (subjects' backs) will be prepped with ChloraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
Study NCT01290978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DuraPrep
Description: The application sites (subjects' backs) will be prepped with DuraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
Study NCT04178057 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB222 3mg/kg
Description: Injection, strength 100mg/bottle, intravenous infusion, 3mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; low dose group.
Study NCT04178057 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB222 5mg/kg
Description: Injection, strength 100mg/bottle, intravenous infusion,5mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; intermediate dose group 1.
Study NCT04178057 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB222 7.5mg/kg
Description: Injection, strength 100mg/bottle, intravenous infusion,7.5mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; intermediate dose group 2.
Study NCT04178057 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB222 10mg/kg
Description: Injection, strength 100mg/bottle, intravenous infusion,10mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; high dose group.
Study NCT03600675 — intervention group
Intervention type: OTHER
Intervention: No intervention element, observational study.
Description: No intervention will be applied to any group. It is an observational study and all measurements are collected during one visit.
Study NCT01177514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin PO. (300MG) 1 capsule the night before surgery, q12hrs the day of surgery and q8hrs for the firt 3 postoperative days.
Study NCT01177514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Sugar pill. One capsule given the night before surgery, q12hrs on the day of surgery and q8hrs for the first 3 postoperative days.
Study NCT02066402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid (BAY119-2631)
Description: 50 % of the participants will be randomized to this arm and will receive 200 mg Tedizolid once daily i.v to oral from 1-6 days
Study NCT02066402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Tedizolid (BAY119-2631)
Description: 50 % of the participants will be randomized to this arm and will receive 200 mg Placebo Tedizolid once daily i.v to oral from 7-10 days
Study NCT02066402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Tedizolid (BAY119-2631)
Description: 50 % of the participants will be randomized to this arm and will receive 200 mg Placebo Tedizolid once daily i.v to oral from 7-10 days
Study NCT02066402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: 50 % of the participants will be randomized to this arm and will receive 600 mg Linezolid twice daily i.v. to oral from 1-10 days
Study NCT02066402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Linezolid
Description: 50 % of the participants will be randomized to this arm and will receive 600 mg Placebo Linezolid twice daily i.v. to oral from 1-10 days
Study NCT03699995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Confocal Microscopy
Description: Undergo confocal microscopy
Study NCT03699995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dermoscopy
Description: Undergo digital dermoscopy